{"DataElement":{"publicId":"7414009","version":"1","preferredName":"Pegaspargase Dose Method Pegaspargase Dosing Type","preferredDefinition":"An indicator of the way Pegaspargase was dosed.","longName":"PEG_DOSE_TP","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"7414005","version":"1","preferredName":"Pegaspargase Dose Method","preferredDefinition":"A complex of polyethylene glycol conjugated with L-asparaginase.  Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting these cells of asparagine and blocking protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle.  The agent also induces apoptosis in tumor cells. Pegylation decreases the enzyme's antigenicity. Asparagine is critical to protein synthesis in leukemic cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. (NCI04)_A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time._A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal.","longName":"7391860v1.0:7414003v1.0","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"7391860","version":"1","preferredName":"Pegaspargase","preferredDefinition":"A complex of polyethylene glycol conjugated with L-asparaginase.  Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting these cells of asparagine and blocking protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle.  The agent also induces apoptosis in tumor cells. Pegylation decreases the enzyme's antigenicity. Asparagine is critical to protein synthesis in leukemic cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. (NCI04)","longName":"C1200","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pegaspargase","conceptCode":"C1200","definition":"A complex of polyethylene glycol conjugated with L-asparaginase.  Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting these cells of asparagine and blocking protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle.  The agent also induces apoptosis in tumor cells. Pegylation decreases the enzyme's antigenicity. Asparagine is critical to protein synthesis in leukemic cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACC9791F-8A7D-4343-E053-4EBD850AD386","latestVersionIndicator":"Yes","beginDate":"2020-08-13","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-08-13","modifiedBy":"ONEDATA","dateModified":"2020-08-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7414003","version":"1","preferredName":"Dose Method","preferredDefinition":"A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.:A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal.","longName":"C25488:C71460","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dose","conceptCode":"C25488","definition":"A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Method","conceptCode":"C71460","definition":"A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AED737D6-8934-2A23-E053-4EBD850A85C5","latestVersionIndicator":"Yes","beginDate":"2020-09-08","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-08","modifiedBy":"ONEDATA","dateModified":"2020-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AED737D6-8945-2A23-E053-4EBD850A85C5","latestVersionIndicator":"Yes","beginDate":"2020-09-08","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-08","modifiedBy":"SETRAKIN","dateModified":"2020-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7414006","version":"1","preferredName":"Pegaspargase Dosing Type","preferredDefinition":"Something distinguishable as an identifiable class based on common qualities.","longName":"7414006v1.0","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"20","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Dose capped","valueDescription":"Dose capped","ValueMeaning":{"publicId":"7414007","version":"1","preferredName":"Dose capped","longName":"7414007","preferredDefinition":"Dose capped","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AED41A7F-EA25-3783-E053-4EBD850A10E4","latestVersionIndicator":"Yes","beginDate":"2020-09-08","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-08","modifiedBy":"ONEDATA","dateModified":"2020-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AED41A7F-EA3E-3783-E053-4EBD850A10E4","beginDate":"2020-09-08","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-08","modifiedBy":"ONEDATA","dateModified":"2020-09-08","deletedIndicator":"No"},{"value":"BSA-based dosing","valueDescription":"Dose Body Surface Area","ValueMeaning":{"publicId":"7414008","version":"1","preferredName":"Dose Body Surface Area","longName":"7414008","preferredDefinition":"A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.: A measure of the 2-dimensional extent of the body surface (i.e., the skin).  Body surface area (BSA) can be calculated by mathematical formula or from a chart that relates height to weight.  BSA is often an important factor in dosing.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dose","conceptCode":"C25488","definition":"A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Body Surface Area","conceptCode":"C25157","definition":"A measure of the 2-dimensional extent of the body surface (i.e., the skin).  Body surface area (BSA) can be calculated by mathematical formula or from a chart that relates height to weight.  BSA is often an important factor in dosing.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AED41A7F-EA4B-3783-E053-4EBD850A10E4","latestVersionIndicator":"Yes","beginDate":"2020-09-08","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-08","modifiedBy":"ONEDATA","dateModified":"2020-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AED41A7F-EA64-3783-E053-4EBD850A10E4","beginDate":"2020-09-08","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-08","modifiedBy":"ONEDATA","dateModified":"2020-09-08","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AED41A7F-EA0F-3783-E053-4EBD850A10E4","latestVersionIndicator":"Yes","beginDate":"2020-09-08","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-08","modifiedBy":"SETRAKIN","dateModified":"2020-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"COG","type":"USED_BY","context":"COG"}],"ReferenceDocuments":[{"name":"If Pegaspargase was given dur","type":"Preferred Question Text","description":"If Pegaspargase was given during this reporting period, how was it dosed?","url":null,"context":"COG"},{"name":"COG CRF Text 2","type":"Alternate Question Text","description":"If Pegaspargase/Calaspargase was given during this reporting period, how was it dosed?","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AED6372E-EBFB-64CC-E053-4EBD850A1320","latestVersionIndicator":"Yes","beginDate":"2020-09-08","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-08","modifiedBy":"WOODC","dateModified":"2020-12-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}